A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis

Haihai Liang1, Chun Zhang, Tao Ban

  • 1Department of Pharmacology, Harbin Medical University, Harbin, Heilongjiang 150081, PR China.

Insights

A novel reciprocal loop between microRNA-21 (miR-21) and transforming growth factor beta receptor III (TGFβRIII) was identified in cardiac fibrosis. Targeting this pathway may offer new strategies for treating myocardial remodeling after infarction.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Fibrosis Research

Background:

  • Cardiac fibrosis impairs heart function by increasing extracellular matrix deposition.
  • The role of microRNA-21 (miR-21) in cardiac fibrosis remains controversial.
  • Transforming growth factor beta receptor III (TGFβRIII) negatively regulates the TGF-β pathway.

Purpose of the Study:

  • To investigate the relationship between miR-21 and TGFβRIII in myocardial fibrosis.
  • To elucidate the role of this interaction in cardiac remodeling following myocardial infarction.

Main Methods:

  • Analysis of miR-21, TGFβRIII, and TGF-β1 expression in mouse hearts post-myocardial infarction.
  • In vitro studies involving cardiac fibroblast transfection with miR-21 or TGFβRIII.
  • Luciferase reporter assays to confirm TGFβRIII as a miR-21 target.
  • Assessment of collagen content and TGF-β pathway activation (p-Smad3).

Main Results:

  • miR-21 and TGF-β1 were upregulated, while TGFβRIII was downregulated in infarcted mouse hearts.
  • miR-21 transfection reduced TGFβRIII expression and increased collagen deposition.
  • TGFβRIII was confirmed as a direct target of miR-21.
  • Overexpression of TGFβRIII inhibited miR-21, reduced collagen, and deactivated the TGF-β1 pathway.

Conclusions:

  • A reciprocal regulatory loop exists between miR-21 and TGFβRIII in myocardial infarction-induced cardiac fibrosis.
  • miR-21 promotes fibrosis by inhibiting TGFβRIII.
  • TGFβRIII counteracts fibrosis by suppressing miR-21 and the TGF-β1 pathway.
  • Targeting the miR-21/TGFβRIII axis presents a potential therapeutic strategy for cardiac remodeling.